No Data
No Data
Kanghui Pharmaceutical (603139.SH): Net profit of 1.086 million yuan in the first quarter decreased by 86.76% year on year
On April 26, Ge Longhui Pharmaceutical (603139.SH) released its first quarter report. Operating revenue was 127 million yuan, up 2.89% year on year, and net profit was 1.086 million yuan, down 86.76% year on year. After deducting non-net loss of 119 million yuan, basic earnings per share were 0.01 yuan.
The A-share diet pill concept fluctuated higher. Kanghui Pharmaceutical went up and down, Kangpeng Technology rose more than 6%, and Nanowei Technology, Haoyuan Pharmaceutical, Medici, and Prius followed suit.
The A-share diet pill concept fluctuated higher. Kanghui Pharmaceutical went up and down, Kangpeng Technology rose more than 6%, and Nanowei Technology, Haoyuan Pharmaceutical, Medici, and Prius followed suit.
Traditional Chinese medicine stocks changed, Kanghui Pharmaceutical lifted its seal, Dali Pharmaceutical rose more than 8%, and Enlightenment Pharmaceutical, Xinguang Pharmaceutical, and Datang Pharmaceutical rose rapidly.
Traditional Chinese medicine stocks changed, Kanghui Pharmaceutical lifted its seal, Dali Pharmaceutical rose more than 8%, and Enlightenment Pharmaceutical, Xinguang Pharmaceutical, and Datang Pharmaceutical rose rapidly.
A-share afternoon review: Shanghai index fell 0.52%, AI concept sector led the decline
The main A-share index opened low. As of the midday close, the Shanghai Index fell 0.52% to 3015.74 points, the Shenzhen Stock Exchange Index fell 1.25%, and the GEM index fell 1.46%.
Chinese medicine stocks rose higher and Kanghui Pharmaceutical rose and stopped in a straight line
Gelonghui March 27 | Kanghui Pharmaceutical went up and down. Dali Pharmaceutical rose more than 7%, while Xiangxue Pharmaceutical, Jianmin Group, Teyi Pharmaceutical, and Longjin Pharmaceutical followed suit.
A-share traditional Chinese medicine stocks rallied rapidly
Gelonghui, March 18 | Dali Pharmaceutical, Kanghui Pharmaceutical, and Jinghua Pharmaceutical went up and down, while Longjin Pharmaceutical, Kangyuan Pharmaceutical, and Xinguang Pharmaceutical followed suit.
No Data